Vanderbilt Enrolling Patients for Pilot Study

Sorafenib Clinical Trial

DTRF has been advised that as of January 4th, the Nexavar/ Sorafenib Phase III clinical trial has met its accrual goal and stopped recruiting new patients. Current participants will continue with their treatment protocol.

"Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future."

- National Institutes of Health

Vanderbilt Enrolling Patients for Study on Extra-Abdominal Desmoid Tumors

Vanderbilt has provided the following information about this study:

Vanderbilt is currently enrolling patients for an institutionally approved imaging based, non-therapeutic, pilot study investigating the use of 18F- FES- PET in adults with extra-abdominal desmoid tumors.

Desmoid tumors have receptors for estrogen and there are non-

receptor mediated effects of estrogen that occur in the body. Some

tumors regress or become quiescent with medications that target estrogen receptors. Vanderbilt Medical Center and the Vanderbilt Ingram Cancer Center would like to learn more about the number and function of these receptors in hopes of better understanding what makes desmoid tumors evolve and start and stop growing so that more personalized treatment regimens can be designed.

More information:

Study summary

Informed consent form/ FAQs

Each participant will be compensated $400.

If you are interested or for more information, please contact Dr. Kate Hartley at [email protected] or Dr. Karen Ayres at [email protected].

This email is intended solely to provide general information for your reference only. Any information contained herein is not intended as medical advice for any individual problem, or as a diagnosis, treatment plan, or recommendation for a particular course of action, and should not be used as a substitute for professional medical advice and services. Please do not delay in obtaining professional medical advice regarding your individual circumstances.